Explore how thrombin generation assays (TGA), FXI inhibitor testing, and translational biomarker strategies enable smarter dose selection, improved outcomes, and optimized global clinical trials.
Explore how thrombin generation assays (TGA), FXI inhibitor testing, and translational biomarker strategies enable smarter dose selection, improved outcomes, and optimized global clinical trials.
Translational Lab Spotlight: FXI Inhibitors & Thrombin Generation Strategy Read More »
Key Flow Cytometry Markers Across Disease Areas Last updated: July 2026 Flow cytometry remains a cornerstone technology for multidimensional cellular analysis in clinical research. As biomarker strategies evolve, its applications continue to expand across therapeutic areas—from oncology and immunology to neurology and rare diseases. At MLM Medical Labs, assays are tailored to each indication, leveraging
Key Flow Cytometry Markers Assessed Across Multiple Disease Categories Read More »
Accelerate Your Clinical Trials with MLM’s Advanced Immunoassay Capabilities Last Updated: June 30, 2026 At MLM, we deliver high-performance, fully customizable immunoassay solutions designed to meet the complex demands of modern preclinical and clinical trials. As a global specialty and central laboratory partner, we combine scientific expertise, advanced technologies, and robust infrastructure across our laboratories
Receptor Occupancy Analysis for Clinical Trials: Powering Precision with Flow Cytometry Updated June 22, 2026 At MLM Medical Labs, our flow cytometry services include advanced receptor occupancy analysis for clinical trials – a critical capability for sponsors developing immunotherapies and targeted biologics. By accurately measuring how investigational drugs bind to their intended receptors, we provide
Receptor Occupancy Analysis – Powering Precision with Flow Cytometry Read More »
Global Gating Strategy in Flow Cytometry: Ensuring Consistency in Clinical Trials Unlocking Consistency in Global Clinical Trials Updated June 4, 2026 In global clinical trials, data consistency is critical. Variability between sites can compromise biomarker analysis, delay decision-making, and create challenges during regulatory review. At MLM Medical Labs, our global gating strategy in flow cytometry
How MLM’s Global Gating Strategy Elevates Your Research Read More »
MLM’s library of nearly 1000 validated assays were developed for diabetes studies – a crucial cretieria for selecting the right Central Lab in metabolic-related clinical trials.
Considerations for Conducting Clinical Studies on Metabolic Conditions Read More »
Clinical trials cost billions, yet promising drugs still fail for preventable reasons. Discover how the wrong laboratory partner can quietly derail a study—and why choosing the right one matters.
When Good Drugs Die in Bad Trials Read More »
MLM Medical Labs leads in IVDR LDT Alzheimer’s biomarker testing with a validated Lumipulse® pTau217/Beta-Amyloid 1-42 plasma assay, enabling reliable, regulatory-compliant data to support global Alzheimer’s clinical trials.
Sponsors of global clinical trials don’t need another oversized, bureaucratic lab — they need a right-sized, science-first partner. Discover how MLM Medical Labs delivers proactive support, direct scientific access, and operational excellence across every phase of complex clinical trials worldwide.
What Global Trial Sponsors Need Now: A Proven, Right-Sized Central Lab Partner Read More »
